Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $14.00 Average Price Target from Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been given a consensus rating of “Hold” by the five analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $14.00.

Several research firms have weighed in on ATRA. The Goldman Sachs Group lowered their target price on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research note on Wednesday, July 17th. Canaccord Genuity Group reiterated a “buy” rating and set a $13.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, August 13th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Finally, Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their price target for the company from $25.00 to $18.00 in a report on Friday, August 16th.

Atara Biotherapeutics Price Performance

ATRA stock opened at $9.58 on Thursday. Atara Biotherapeutics has a 1-year low of $4.96 and a 1-year high of $39.50. The firm has a fifty day moving average price of $8.12 and a two-hundred day moving average price of $10.76. The firm has a market cap of $46.15 million, a price-to-earnings ratio of -0.18 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The business had revenue of $28.64 million for the quarter, compared to analysts’ expectations of $48.30 million. As a group, analysts expect that Atara Biotherapeutics will post -12.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in Atara Biotherapeutics by 8,916.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after purchasing an additional 4,903,159 shares during the period. Acadian Asset Management LLC lifted its holdings in Atara Biotherapeutics by 49.5% in the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after purchasing an additional 873,133 shares during the period. Redmile Group LLC lifted its holdings in Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after purchasing an additional 156,863 shares during the period. BNP Paribas Financial Markets lifted its holdings in Atara Biotherapeutics by 29.3% in the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 86,842 shares during the period. Finally, Delap Wealth Advisory LLC acquired a new stake in Atara Biotherapeutics in the first quarter worth about $29,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.